OVARIAN CANCER

【Medical industry network HealthDayNews2003 According to the July 3 - now on the younger female epithelial ovarian cancer, some important information: your chances of survival much more than older patients.

In July, "Obstetrics and Gynecology" (Obstetrics andGynecology), the journal published a new study, the researchers found: diagnosis of advanced epithelial ovarian cancer in women aged under 45 of the 5-year survival than those over the age of 45 is two times bigger. "If all other aspects of the same, young patients can live better," the author, Stamford University professor Chen (JohnChan): In fact, even if it is possible to study the impact of factors, such as other health problems, age patients still live better.

Tags: age, blood, cancer, clinical, diagnosis, early, gene, group, groups, growth, method, ovarian, patients, positive, rate, response, study, surgery, survival, time, tumor, women

Serous cystadenoma
Zhu serous tumor of the kidney from the body cavity epithelium, is the most common tumors of the ovary. According to national statistics, the total of 2007-09-07 16:00:00.1% of ovarian tumors common in women aged 30-40. The unilateral nature, but there are also many of the bilateral. Simple solution can be divided into gland capsule and two papillary serous cystadenoma.

Tags: abdominal, age, amenorrhea, annex, anti, benign, bleeding, blood, body, breast, cancer, carcinoma, cases, cause, cell, cells, children, clinical, cyst, cystic, cysts, diagnosis, early, eat, ert, estrogen, gene, group, groups, growth, incidence, increased, malignant, mass, metastasis, metastatic, oppression, ovarian, ovary, patients, pelvic, poor, prognosis, protein, quality, radiation, rate, resection, surface, surgery, surgical, survival, symptoms, time, treatment, tumor, tumors, usually, uterine, women

Epithelial ovarian cancer in the United States is a relatively rare in Gynecologic Oncology, 2004, there were approximately 25,580 cases of new onset patients, 16,090 cases patients died. The majority of patients with advanced cancer, treatment for surgical resection and postoperative to platinum-based chemotherapy. During the past 10 years, chemotherapy improved survival rates improve, and recurrent tumor treatment more effective. In addition, the genetic risk factors for making in-depth understanding of the prevention strategy to become individualized approach to bilateral tubal women - ovarian surgery. This report summarized the clinical characteristics of epithelial ovarian, after reports focus on the treatment of the latest developments.

Tags: age, brca1, breast, cancer, carcinoma, cases, cause, chemotherapy, clinical, diagnosis, drug, drugs, early, eat, ert, estrogen, examination, family, gene, group, groups, history, incidence, increased, life, malignant, mutation, ovarian, ovary, patients, pelvic, preventive, protein, rate, reduce, resection, risk, screening, second, study, surface, surgery, surgical, survival, syndrome, therapy, time, treatment, tumor, usually, women

I. Overview

With the aging of the global trend of development, improve the economic status of women, more and more women start hormone replacement therapy (Hormone Replacement Therapy, HRT), to improve access to after menopause due to the decrease in the level of sex hormones related to various diseases. Clear evidence that: postmenopausal women with age, the incidence of coronary heart disease increased by about four times the fracture due to osteoporosis by 20%, died of complications due to pelvic fracture rate of 30%, after the 65-year-old Alzheimer's incidence rate increase every year <BR> and Application HRT can peer groups coronary heart disease risk 50% Alzheimer's risk reduced three times, especially worth mentioning is significantly reduced the incidence of rectal cancer. Long-term use of HRT cancer risk reduced year by year. HRT can also greatly improve the menopause, postmenopausal women with disease or ovarian surgery, radiotherapy in patients with a series of artificial menopause syndrome.

Tags: age, benign, blood, body, brca1, breast, cancer, carcinoma, care, cases, cause, cell, cells, clinical, cyst, cystic, diagnosis, diet, drug, early, eat, ert, estrogen, family, fat, gene, grams, group, groups, growth, gynecological, history, hrt, incidence, increased, injection, intravenous, life, lymph, malignant, metastasis, method, mutation, node, ovarian, patients, pelvic, positive, protein, quality, radiotherapy, rate, reduce, residual, risk, screening, second, study, surgery, surgical, survival, syndrome, therapy, time, treatment, tumor, tumors, usually, uterine, women

Ovarian cancer is the female reproductive system cancer one of the three, as misprision of clinical symptoms, the lack of an effective method for early diagnosis, over 80% of patients had treatment for late mortality gynecologic malignancies in the first place. CA-125 tumor marker specificity is not strong, there false positive, we can not separate screening for ovarian cancer. High-throughput protein groups for the study of information technology and biological tools for ovarian cancer biomarkers of mass rapid screening provided a powerful weapon.

Tags: age, anti, benign, blood, body, cancer, cases, cell, cells, clinical, diagnosis, early, eat, eggs, gene, group, groups, increased, malignant, mass, method, ovarian, patients, positive, prostasin, protein, rate, screening, study, surgery, symptoms, treatment, tumor, tumors

Tumor resistance of the tumor cells to anticancer drugs that showed no reaction of the state of ovarian cancer chemotherapy failure is the central link.

In the cell level can be divided into the inherent resistance of resistance and acquired resistance of the two. Acquired resistance of ovarian cancer is the main reason for resistance. Resistance of ovarian cancer treatment at the following categories of major new strategy.

; To detoxification pathway-based chemotherapy

1. Resistance

Tags: age, anti, blood, body, cancer, cases, cell, cells, chemotherapy, clinical, dose, drug, drugs, eat, group, groups, growth, method, ovarian, paclitaxel, patients, poor, prognosis, protein, rate, reduce, response, risk, second, tea, therapy, time, toxicity, treatment, tumor, tumors

According to an obstetrics and gynecology oncology groups (GOG) study said that the smaller Phase III epithelial ovarian cancer patients, carboplatin and Taxol toxicity smaller, easier to use, the effect is less than cisplatin plus paclitaxel.

The non-randomized study data show that in advanced epithelial ovarian cancer, carboplatin and paclitaxel very effective, but less than the toxicity of cisplatin-based drugs, but its smaller, have unresectable Stage III cancer effects remain unknown. To this end, Philadelphia Fox Kaiser Cancer Center Aozhuoershi (Robert F. Ozols), and colleagues conducted a test to detect carboplatin and paclitaxel combined with cisplatin is secondary. 792 patients participated in this study, 400 were randomly assigned cisplatin (75 mg/m2) and paclitaxel (135 mg/m2) 24-hour infusion (group I), 392 with carboplatin (area under the curve of 7.5) and paclitaxel (175 mg / m2) 3-hour infusion (Group II). The two groups were 85% and 87% of the patients completed six cycles of treatment.

Tags: age, blood, cancer, carboplatin, cell, cisplatin, clinical, drug, drugs, eat, ert, group, groups, gynecological, infusion, ovarian, paclitaxel, patients, rate, second, study, survival, taxol, time, toxicity, treatment